Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Autoliv becomes a Signatory of United Nations Global Compact

(Stockholm, Sweden, 3 May, 2019) – Autoliv, Inc. (NYSE: ALV and SSE: ALIVsdb), the worldwide leader in automotive safety systems, becomes a Signatory of United Nations Global Compact.Global Compact is the world’s largest corporate sustainability initiative, calling companies to align strategies and operations with universal principles on human rights, labor, environment and anti-corruption, and take action that advance societal goals. Today, almost 10,000 companies in 162 different countries around the world have joined the initiative. UN Global Compact supports companies to do business

Investor Call 2018 Annual report and Accounts of Corral Petroleum Holdings AB

As previously announced an international conference call for investors and analysts will be held today, the 3rd of May, 2019 at 3:00 pm CET.Please see attached file for the presentation that will be used in the scheduled international conference call. The dial-in number is: Standard International Access +44 (0) 20 3003 2666 Stockholm +46 (0) 8 50520424 New York +1 212 999 6659 Berlin +49 (0) 30 3001 90612 Copenhagen +45 3271 4573 Helsinki +358 9 2319 5437 Norway Local Oslo +47 2 156 3318 Paris +33 (0) 1 7099 4740 The meeting code is Corral FY2018 For further

The European Commission has appealed the General Court of the European Union’s decision on certain Belgian tax rulings

Stockholm, Sweden, May 3, 2019: The European Commission has appealed the General Court of the European Union’s annulment of the European Commission’s decision of January 11, 2016 that certain Belgian tax rulings granted to multinationals, among others Atlas Copco, with regard to “Excess Profit” shall be considered as illegal state aid.On February 14, 2019, the General Court of the European Union annulled the decision. The European Commission has now appealed the General Court’s decision to the European Court of Justice. As communicated earlier Atlas Copco paid the amount to cover the

Swedish Steel Prize 2019 is now open for entry

Applications are now being accepted for the Swedish Steel Prize 2019, the steel industry’s most prestigious award, which celebrates its 20th anniversary this year. The Swedish Steel Prize is an award for ideas and products that have an impact on future steel solutions, and it attracts competitors from across the world. It will be awarded on November 14th, 2019 in Stockholm, Sweden as part of the Swedish Steel Prize 2019 event. Applications are now being accepted. This year marks the 20thanniversary of the Swedish Steel Prize. Over the past two decades, the award has inspired

Elkem Silicones at Electric & Hybrid Vehicle Technology Expo Europe 2019

Elkem Silicones showcases advanced materials for Battery technology and Electronic components at Electric & Hybrid Vehicle Technology Expo Europe 2019.Our global technical team will present you our solutions for thermal management, fire protection and assembly at Electric & Hybrid Vehicle Technology Expo Europe in Stuttgart, May 7th to 9th, 2019. At Elkem Silicones, we are playing an active role in developing next generation materials that meet the requirements of electric and hybrid vehicle applications. Discover our solutions for thermal management (thermally conductive adhesives, gap

April: Monthly statistics

The number of customers at Avanza has during 2019 increased by 46,200, amounting to 12,600 new customers in April. This resulted in 883,300 customers at the end of the month. Net inflow in April was SEK 3,320m*, amounting to SEK 10,900m* during 2019.+-------------------------+---------+--+---------+--------+---------+-------+| | April | | March | Change| April | Change|| | 2019 | | 2019 | month %| 2018 |year % |+-------------------------+---------+--+---------+--------+---------+-------+|  |

All patients enrolled in Enzymatica’s German placebo-controlled multicentre study with ColdZyme

Enzymatica has now finalized the enrolment to its prospective double-blind, placebo-controlled multicentre study to evaluate the effects of ColdZyme® on the common cold. In total about 700 patients have been enrolled at ten study centres in Germany. Of the enrolled patients more than 400 have caught a cold, which is according to plan for the study.The overall goal of the study is to evaluate the efficacy of ColdZyme on the common cold. The primary objective is to assess the impact of ColdZyme on quality of life during a common cold period, with the Wisconsin Upper Respiratory Symptom Survey

Atlas Copco has acquired a German compressor distributor with a strong focus on service

Stockholm, Sweden, May 3, 2019: Atlas Copco has acquired Bold & Cichos GbR. Besides offering compressors and service the company has specialist knowledge in engineering of air package container solutions.Bold & Cichos Lackier- & Lufttechnik is located in Waldfischbach-Burgalben in the south-west of Germany. The company has around 15 employees. “We see possibilities to increase our coverage in the region and our knowledge in designing and manufacturing air package container solutions”, said Vagner Rego, Business Area President Compressor Technique. The purchase price is not material

Invitation to the Opus Q1 2019 report presentation

Opus Group AB (publ) will release its first quarter 2019 report on Tuesday May 14, 2019, at 08:30 CET. CEO Lothar Geilen and CFO Linus Brandt will present the company’s results on the same day at 10:00 CET.The presentation will be held in English. To join the webcast please click on the following link:https://edge.media-server.com/m6/p/zdkq9uoz To connect to the conference call please dial in 5-10 minutes prior to the start time, using the conference Confirmation Code below. Confirmation Code: 3568198 Participants, Local number - Sweden: +46 8 506 92180Participants, Local

Scandion Oncology A/S Annual Report 2018 published

Scandion Oncology A/S hereby publishes the Annual Report for 2018. The Annual Report 2018 is available on the company's website (www.scandiononcology.com).For further information regarding Scandion Oncology, please contact: Nils Brünner, CEO Phone: +45 26 14 47 08 E-mail: nb@scandiononcology.com  www.scandiononcology.com Scandion Oncology A/S is a biotechnology company founded in 2017 for the purpose of addressing and tackling one of the greatest challenges in modern oncology – the effective treatment of cancer which contains drug resistant cell clones or which has developed

Invitation – First quarter results presentation 2019

Invitation, Hillerstorp 3rd of May 2019, 08:30 CET Troax Group´s report for the first quarter 2019 will be published at 12:30 CET, May 14. The report and a presentation will be available on https://www.troax.com/en/investerare/financial-reportsThomas Widstrand, President and CEO, will present the financial results on a conference call the same day at 17:00 CET. The conference will be held in English. In order to participate in the conference call, please use the dial-in details below. Callers are encouraged to dial in 5-10 minutes in advance as a short registration with the call

Peab receives new base contract for road maintenance in Uppsala

Peab has been commissioned to take responsibility for operation and maintenance of public roads in Uppsala for four years. The customer is the Swedish Transport Administration and the cumulative worth of the contract is SEK 193 million.The commission comprises winter road and bare ground road maintenance. The contract is spread over four years, starting 1 September 2019, with an option for an extension of one to two years. “Winter and summer road maintenance is an important job that carries considerable responsibility. We are proud that we have been entrusted with the care of public

MEDIVIR AB – INTERIM REPORT, JANUARY – MARCH 2019

Clinical studies progress according to plan January – MarchSignificant events during the quarter · The phase II study of birinapant in combination with Keytruda® in colorectal cancer patients progresses according to plan. A futility analysis is planned to be conducted no later than the fourth quarter of 2019. · The phase Ia study of MIV-818 in patients with liver cancer is planned to be completed during the second quarter of 2019. · As a result of the restructuring of Medivir, there is no longer any preclinical research conducted in the company. The new organization focuses

First XPS™ sold to Canada

Vancouver Coastal Health in Vancouver is the first clinic in Canada that has decided to use the XPS™. The purpose is to start an EVLP (Ex Vivo Lung Perfusion)-program to utilize more donated lungs which will benefit patients with end stage lung diseases.There are approximately 300 lung transplants performed every year at four clinics in Canada, whereof Vancouver on the Canadian west coast makes the second most. Clinics in Canada has already from the beginning of lung transplantation been in the research forefront and also amongst the first to employ new technology. The percentage of lung

PowerCell participates at the international fuel cell fair CHFCE in Beijing, China

PowerCell Sweden will participate at the international fuel cell and hydrogen fair, CHFCE, taking place in Beijing, China between May 6-7.This is the fourth time the China International Hydrogen and Fuel Cell Conference & Exhibition is being arranged. China is a highly interesting market for PowerCell given the Chinese Government’s recent decision to shift-over subsidies from battery vehicles to vehicles electrified using fuel cells and hydrogen. The shift in policy has led to an increased interest for PowerCell’s technology from Chinese customers.   At the fair PowerCell will present

INTERIM REPORT, JANUARY-MARCH 2019

Sales growth and improved EBITDA driven by acquisitions and prioritised brandsJanuary-March 2019 (first quarter) · Net sales amounted to SEK 786 million (610). · EBITDA amounted to SEK 73 million (57) before items affecting comparability, corresponding to a margin of 9.3 percent (9.3). · Profit for the period was SEK 4 million (39), corresponding to earnings per share of SEK 0.08 (0.85) before and after dilution. · Free cash flow amounted to SEK -42 million (-4). · Restructuring costs for an efficiency programme for the Group’s Nordic operations were charged to the period’s

Eyeonid Group AB (publ) issues SEK 3 million of convertibles notes

Eyeonid Group issues SEK 3 million of convertibles notes to European Select Growth Opportunities Fund (“Investor”). The issuance of SEK 3 million convertible notes is within the framework of the financing agreement with the Investor announced in a press release on January 31, 2018. The parties have agreed that no related warrants will be issued, neither to the Investor nor to existing shareholders within this transaction.Facts about the Notes ·  The principal amount per Note is SEK 100,000. ·  The Notes are interest-free. ·  The maturity of the Notes is 12 months from the date of

Invitation to presentation of Balco’s first quarter report 2019

Balco’s interim report for the first quarter 2019 will be published at 08:00 CET on May 21, 2019. A web-cast telephone conference will be held at 09:00 CET the same day, where CEO and President Kenneth Lundahl and CFO Michael Grindborn will present the results for the first quarter 2019.A possibility will be given to ask questions via the webcast and follow the presentation material live. The webcast, which afterwards also will be available on demand, will be accessible at Balco’s financial website, www.balcogroup.se or via the following link http://www.financialhearings.com/event/11770.The

Attendo’s report for the first quarter 2019: Strong growth with continued margin pressure

Attendo shows continued strong growth during an otherwise challenging first quarter of 2019. There are bright spots in home care operations, sales of new beds, and high and stable occupancy in mature units. Meanwhile, the result is negatively affected by stricter staffing requirements in Finland and the high rate of openings of new units.President and CEO Martin Tivéus comments on the report “The start of 2019 has been challenging for Attendo. There are however several bright spots – we continued to make progress in home care, sales of new beds increased, we demonstrated strong growth in

Qternmet XR approved in the US for type-2 diabetes

3 May 2019 07:00 BST  Qternmet XR approved in the US for the treatment of type-2 diabetes The US Food and Drug Administration (FDA) has approved Qternmet XR (dapagliflozin, saxagliptin and metformin hydrochloride) extended release tablets as an oral adjunct treatment to diet and exercise to improve glycaemic control in adults with type-2 diabetes (T2D). The approval is based on two Phase III trials, which evaluated combinations of dapagliflozin and saxagliptin on a background of metformin over 24 weeks, in patients with inadequately-controlled T2D. In one trial, treatment with

Invent Medic updates on current market activities for the company’s product  Efemia Bladder Support

Invent Medic announces that the company’s current market activities for the innovative medical technology product Efemia Bladder Support is starting to show results in the form of an increased knowledge about the product and a successive sales growth in 2019.The market activities for Efemia are aimed at both health care entities and organisations promoting women’s health, as well as directly towards potential customers. They are conducted by the company and through its distributors. A substantial share of the marketing work aimed at health care entities involves contacting and visiting

Interim report January-March 2019

January-March 2019 · Net sales were 299.3 MSEK (280.1), an increase of 6.9% from the equivalent quarter in 2018. · Operating income increased to 39.5 MSEK (16.8), an operating margin of 13.2% (6.0). · Earnings per share were 2.28 SEK (0.98). · Cash flow after investments was -1.0 MSEK (-0.2). Significant events during and after the quarter · Mikael Östbring left his post as Nordic sales and marketing director in January. · Ole Sander left his post as International sales and marketing director and managing director FMMMG Denmark in April. Statement from the CEO

BioGaia launches BioGaia Osfortis – a new product for the prevention of osteoporosis

The USA will be the first market to launch BioGaia’s new product for bone health, BioGaia Osfortis. The product will be marketed by Everidis Health Sciences in the US and will be available from mid-May 2019.“Osteoporosis is a common, global disease. Consequently, a way of maintaining good bone health and preventing osteoporosis constitutes an important focus area for BioGaia. I am very happy that our partner Everidis will launch BioGaia Osfortis in the USA. It is an important market with great potential for this product. Step by step more markets will launch BioGaia Osfortis,” says Isabelle

Neste Corporation - Managers' Transactions, Kähkönen (acquisition)

Neste Corporation, Managers' Transactions, 3 May 2019 at 9 am. (EET)____________________________________________ Person subject to the notification requirementName: Kähkönen, MattiPosition: Member of the Board/Deputy memberIssuer: Neste OyjLEI: 5493009GY1X8GQ66AM14 Notification type: INITIAL NOTIFICATIONReference number: 5493009GY1X8GQ66AM14_20190502171444_2____________________________________________ Transaction date: 2019-05-02Venue: NASDAQ HELSINKI LTD (XHEL)Instrument type: SHAREISIN: FI0009013296Nature of the transaction: ACQUISITION Transaction

There are no items matching the current filter
There are no more items matching the current filter
Back to top